Should Value Hunters Buy Pfizer Inc. (NYSE: PFE) Stock? – Stocks Register
Home  »  Companies   »  Should Value Hunters Buy Pfizer Inc. (NYSE: PFE) S...

Should Value Hunters Buy Pfizer Inc. (NYSE: PFE) Stock?

Pfizer Inc. (NYSE:PFE) price on Thursday, August 26, fall -0.27% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $47.38.

A look at the stock’s price movement, the close in the last trading session was $47.51, moving within a range at $47.30 and $48.16. The beta value (5-Year monthly) was 0.67 while the PE ratio in trailing twelve months stood at 21.64. Turning to its 52-week performance, $51.86 and $32.79 were the 52-week high and 52-week low respectively. Overall, PFE moved 9.04% over the past month.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Pfizer Inc.’s market cap currently stands at around $266.08 billion, with investors looking forward to this quarter’s earnings report slated for Oct 25, 2021 – Oct 29, 2021. The company has a Forward Dividend ratio of 1.56, with its dividend yield at 3.29%. As such, investors might be keen on an upside in the stock’s price ahead of the scheduled earnings report. Analysts project the company’s earnings per share (EPS) to be $1.08, which has seen fiscal year 2021 EPS growth forecast to increase to $4.12 and about $3.59 for fiscal year 2022. Per the data, EPS growth is expected to be 85.60% for 2021 and -12.90% for the next financial year.

Analysts have a consensus estimate of $22.87 billion for the company’s revenue for the quarter, with a low and high estimate of $20.99 billion and $26.26 billion respectively. The average forecast suggests up to a 88.60% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue for 2021 to grow to $81.23 billion, representing a 93.80% jump on that reported in the last financial year.

Revisions could be used as tool to get short term price movement insight, and for the company that in the past seven days was no upward and no downward review(s). Turning to the stock’s technical picture we see that short term indicators suggest on average that PFE is a 100% Buy. On the other hand, the stock is on average a 100% Buy as suggested by medium term indicators while long term indicators are putting the stock in 100% Buy category.

The technical evaluation for the stock shows the PEG ratio is 1.76, with PFE’s current price about 0.94% and 10.74% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 56.16, while 7-day volatility ratio is 2.84% and 2.84% in the 30-day chart. Further, Pfizer Inc. (PFE) has a beta value of 0.71, and an average true range (ATR) of 1.39.

In the market, a comparison of Pfizer Inc. (PFE) and its peers suggest the former has performed considerably weaker. Data shows PFE’s intraday price has changed -0.27% in last session and 31.39% over the past year. Comparatively, Johnson & Johnson (JNJ) has moved -0.53% on the day and only 13.79% in the past 12 months. Looking at another peer, we see that Eli Lilly and Company (LLY) price has dipped -0.97% on the day. However, the stock is 75.08% off its price a year ago. Moreover, Abbott Laboratories (ABT) is also up 0.59% in trading on the day while keeping a an uptrend of 21.59% over the past year. If we look at the PE ratio, we find that Pfizer Inc.’s ratio stands at 21.64 compared to Johnson & Johnson’s 26.06 and Eli Lilly and Company’s 39.28. Elsewhere, the overall performance for the S&P 500 and Dow Jones Industrial shows that the indexes are down -0.58% and -0.54% respectively in the last trading.

If we refocus on Pfizer Inc. (NYSE:PFE), historical trading data shows that trading volumes averaged 62.69 million over the past 10 days and 30.94 million over the past 3 months. The company’s latest data on shares outstanding shows there are 5.60 billion shares.

>> 7 Top Picks for the Post-Pandemic Economy <<

The 0.04% of Pfizer Inc.’s shares are in the hands of company insiders while institutional holders own 67.40% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 59.77 million on Jun 14, 2021, giving us a short ratio of 2.62. The data shows that as of Jun 14, 2021 short interest in Pfizer Inc. (PFE) stood at 1.07% of shares outstanding, with shares short rising to 57.32 million registered in May 13, 2021. Current price change has pushed the stock 28.72% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the PFE stock continues to rise going into the next quarter.

Leave a Comment

Your email address will not be published. Required fields are marked *

Related Posts

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam